Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD38 pretreated allogeneic NK cells
- Development stage
- Preclinical
- Lead developer
- Maria Skłodowska-Curie National Research Institute of Oncology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CD38 pretreated allogeneic NK cells (also referred to as PBNK-CD38- cells) is an investigational allogeneic natural killer (NK) cell therapy being developed for the treatment of multiple myeloma. Developed by PrimeCell Advanced Therapy in collaboration with the University of Ostrava and other partners, the therapy involves expanding peripheral blood-derived NK (PBNK) cells and pretreating them in vitro with an anti-CD38 monoclonal antibody (such as daratumumab). This pretreatment selectively induces the fratricide of CD38-positive NK cells, yielding a homogeneous population of CD38-negative NK cells. By eliminating CD38 expression on the effector NK cells, this approach prevents self-destruction (fratricide) when the cells are co-administered with anti-CD38 monoclonal antibodies, thereby enhancing antibody-dependent cellular cytotoxicity (ADCC) against CD38-expressing multiple myeloma cells.
- Other names
- anti-CD38-pretreated NK-cell therapyanti-CD-38-pretreated NK-cell therapyanti-CD 38-pretreated NK-cell therapyPBNK-CD38-PBNK-CD-38-PBNK-CD 38-PBNK-CD38- cellsPBNK-CD-38- cellsPBNK-CD 38- cells
02
Targets
CD38 (Cluster of Differentiation 38)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on anti-CD38 pretreated allogeneic NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD38 pretreated allogeneic NK cells.